Reading Time: 6 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis. Some of this weight loss may be due to a person experiencing difficulties with chewing and swallowing because of increased muscle weakness. It could be due to a lack of…
Reading Time: 7 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis. Some of this weight loss may be due to a person experiencing difficulties with chewing and swallowing because of increased muscle weakness. It could be due to a lack of…
Reading Time: 5 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis. Some of this weight loss may be due to a person experiencing difficulties with chewing and swallowing due to increasing muscle weakness, a lack of appetite due to tiredness, anxiety…
Reading Time: 5 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis. Some of this weight loss may be due to a person experiencing difficulties with chewing and swallowing because of increased muscle weakness. It could be due to a lack of…
Reading Time: 6 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis. Some of this weight loss may be due to a person experiencing difficulties with chewing and swallowing because of increased muscle weakness. It could be due to a lack of…
Reading Time: 12 minutes Despite decades of research, we still do not fully understand why some people get MND, but studies in cell and animal models of the disease suggest that astrocytes and microglia cells are key players in the process, and a potential target for new therapies to moderate oxidative stress, reduce mitochondrial damage, and limit glutamate excitotoxicity…
Reading Time: 7 minutes Shyuan’s talk was titled ‘Investigating the role of hypermetabolism in ALS’ (C06 in the abstract book) and discussed the research being carried out by her team to try and understand the mechanisms driving hypermetabolism in ALS and what hypermetabolism means clinically for people living with the disease. This blog details Shyuan’s work and looks closely at her observations on hypermetabolism in relation to ALS.
Reading Time: 5 minutes What is a clinical endpoint?
A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.
To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.
Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…
Reading Time: 3 minutes Welcome to the final blog, number 22, in our Symposium Blogathon – counting down to the 32nd International Symposium on ALS/MND. If you’ve been here since blog number 1, published all the way back at the beginning of November, then well done! I hope you’ve found the blogs interesting and informative. If this is the…
